Onderneming Hansa Biopharma AB Nasdaq Stockholm
Aandelen
SE0002148817
Biotechnologie & Medisch Onderzoek
Vakgebied
Verkoop per activiteit
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Antibody-cleaving Enzyme Technology Platform
100,0
%
| 155 | 100,0 % | 134 | 100,0 % | -13,22% |
Verkoop per regio
SEK in miljoen | 2022 | Gewicht | 2023 | Gewicht | Delta |
---|---|---|---|---|---|
Europe (excluding Sweden)
79,6
%
| 86 | 55,4 % | 107 | 79,6 % | +24,66% |
North America
20,4
%
| 64 | 41,6 % | 27 | 20,4 % | -57,34% |
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Søren Tulstrup
CEO | Chief Executive Officer | 59 | 20-03-18 |
Hitto Kaufmann
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/12 |
Achim Kaufhold
CTO | Chief Tech/Sci/R&D Officer | 66 | 29-05-20 |
- | - | ||
Klaus Sindahl
IRC | Investor Relations Contact | - | 29-04-19 |
Matthew Shaulis
PRN | Corporate Officer/Principal | - | 16-03-23 |
Max Sakajja
PRN | Corporate Officer/Principal | 43 | 01-01-17 |
Anne Lanner
HRO | Human Resources Officer | 55 | 18-01-19 |
Vincenza Nigro
PRN | Corporate Officer/Principal | - | 17-09-18 |
Magnus Korsgren
PRN | Corporate Officer/Principal | 55 | 01-04-21 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Director/Board Member | 73 | 29-05-18 | |
Peter Nicklin
CHM | Chairman | 61 | 30-06-22 |
Mats Blom
BRD | Director/Board Member | 59 | 22-05-19 |
Eva Nilsagård
BRD | Director/Board Member | 60 | 22-05-19 |
Hilary Malone
BRD | Director/Board Member | 59 | 12-05-21 |
Andreas Eggert
BRD | Director/Board Member | 56 | 29-05-18 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 0 | 2 362 445 | 0 | 2 362 445 ( 100,00 %) | 88,64 % |
Aandeel B | 1 | 52 443 962 | 48 580 000 ( 92,63 %) | 0 |
Participaties
Naam | Aandelen | % | Totale waarde |
---|---|---|---|
HANSA BIOPHARMA AB 100.00% | 2 598 012 | 100.00% | 7 070 516 $ |
Bedrijfsgegevens
Sector
Verkoop per regio
Vaira. 1 jan. | Kapi. | |
---|---|---|
+17,96% | 44,96 mld. | |
+1,17% | 42,65 mld. | |
+48,77% | 41,85 mld. | |
-4,27% | 29,04 mld. | |
+11,42% | 26,08 mld. | |
-21,39% | 19,03 mld. | |
+4,86% | 12,75 mld. | |
+27,29% | 12,06 mld. | |
-3,50% | 11,75 mld. |